International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design

2018/04/21 by David J. Maron, Judith S. Hochman, Sean M. O’Brien +14 · 25 citations
Medicine · #Cardiac Health and Mental Health #Cardiac Imaging and Diagnostics #Cardiovascular Health and Risk Factors

paper · doi:10.1016/j.ahj.2018.04.011

Cited by

• International Study of Comparative Health Effectiveness with Medical and Invasive Approaches-Chronic Kidney Disease (ISCHEMIA-CKD): Rationale and design. [europepmc]
• Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. [europepmc]
• Clinical significance of chronic myocardial ischemia in coronary artery disease patients. [europepmc]
• Myocardial blood flow reserve assessed by positron emission tomography myocardial perfusion imaging identifies patients with a survival benefit from early revascularization. [europepmc]
• Transient ischaemic dilation and post-stress wall motion abnormality increase risk in patients with less than moderate ischaemia: analysis of the REFINE SPECT registry. [europepmc]
• Diagnosis of patients with angina and non-obstructive coronary disease in the catheter laboratory. [europepmc]
• Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Function and CT Coronary Angiogram (CorCTCA) study. [europepmc]
• Association of Sex With Severity of Coronary Artery Disease, Ischemia, and Symptom Burden in Patients With Moderate or Severe Ischemia: Secondary Analysis of the ISCHEMIA Randomized Clinical Trial. [europepmc]
• Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. [europepmc]
• Initial Invasive or Conservative Strategy for Stable Coronary Disease. [europepmc]
• Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease in Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial. [europepmc]
• Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons. [europepmc]
• Assessing health-related quality of life among patients with peripheral artery disease: A review of the literature and focus on patient-reported outcome measures. [europepmc]
• CT Angiography Followed by Invasive Angiography in Patients With Moderate or Severe Ischemia-Insights From the ISCHEMIA Trial. [europepmc]
• Natural History of Patients With Ischemia and No Obstructive Coronary Artery Disease: The CIAO-ISCHEMIA Study. [europepmc]
• Outcomes in the ISCHEMIA Trial Based on Coronary Artery Disease and Ischemia Severity. [europepmc]
• The Prognostic Significance of Neutrophil to Lymphocyte Ratio (NLR), Monocyte to Lymphocyte Ratio (MLR) and Platelet to Lymphocyte Ratio (PLR) on Long-Term Survival in Off-Pump Coronary Artery Bypass Grafting (OPCAB) Procedures. [europepmc]
• Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trial. [europepmc]
• Chronic obstructive pulmonary disease and atherosclerosis: common mechanisms and novel therapeutics. [europepmc]
• Deep Learning for Explainable Estimation of Mortality Risk From Myocardial Positron Emission Tomography Images. [europepmc]
• Survival After Invasive or Conservative Management of Stable Coronary Disease. [europepmc]
• Impact of Complete Revascularization in the ISCHEMIA Trial. [europepmc]
• Complete Revascularization and Angina-Related Health Status in the ISCHEMIA Trial. [europepmc]
• Atherosclerosis quantification and cardiovascular risk: the ISCHEMIA trial. [europepmc]
• Clinical Updates in Coronary Artery Disease: A Comprehensive Review. [europepmc]